.png)
Where Regenerative Science Meets Aesthetics
World-leading cGMP-grade platform to bring your products from development to the market
.png)
Where Regenerative Science Meets Aesthetics
We optimize our production and quality control, so batch-to-batch variance is minimal
We produce exosomes tailored to your needs and strategic goals
Our validation pipeline prioritizes excellence
.png){kind=icon}
Essential Solutions
facilities
GMP-Graded Exosome CDMO
Our versatile, GMP-compliant platform adapts to specific cell lines for faster optimization and regulatory alignment, while bespoke workflows accelerate research and scalability
Scalable production suitable for preclinical, clinical trial, and commercial applications
.png){kind=icon}
Meticulous quality control from raw material selection to final product release, ensuring adherence to international standards
Unlike conventional freeze-drying, which can compromise protein integrity and bioactivity, our patented lyophilization technology preserves exosome structure and functionality. Through precise low-temperature control and optimized drying condition
Premium Exosome Material Provider
.png)
Isolated from plant stem cell cultures like Centella asiatica and turmeric, these exosomes are rich in natural bioactive compounds that support antioxidant and skin repair
Extracted from animal cell cultures such as salmon and eel, these exosomes are formulated with bioactive substances beneficial for skin and tissue repair
Derived from probiotic sources, such as Lactobacillus, these exosomes show promising potential for gut health regulation and immune system enhancement
Isolated from plant stem cell cultures like Centella asiatica and turmeric, these exosomes are rich in natural bioactive compounds that support antioxidant and skin repair
Extracted from animal cell cultures such as salmon and eel, these exosomes are formulated with bioactive substances beneficial for skin and tissue repair
Derived from probiotic sources, such as Lactobacillus, these exosomes show promising potential for gut health regulation and immune system enhancement
Advanced Exosome Lyophilization
Lyophilized exosome powder offers extended shelf life and improved transport efficiency
Reduced storage and logistics costs, with rapid reconstitution for immediate use
Our lyophilized exosomes provide a robust, flexible solution for modern product development
LUXTHERA is a leading provider of regenerative science in aesthetic applications
LUXTHERA is a global leader in exosome innovation, delivering medical-grade, next-generation exosome materials and full-spectrum CDMO solutions to the world’s most forward-thinking brands in aesthetics, wellness, nutrition, and pharmaceuticals. LUXTHERA combines advanced purification, molecular characterization, and proprietary lyophilization technology to produce ultra-pure, highly bioactive exosomes under strict GMP compliance — setting new global benchmarks for quality, safety, and performance.
Our scientifically curated exosome portfolio includes premium plant-derived exosomes (e.g., Centella asiatica) renowned for antioxidant, anti-inflammatory, and skin-repair benefits; marine animal-derived exosomes (salmon, eel) with potent regenerative and anti-aging effects; and next-generation microbial-derived exosomes (e.g., Lactobacillus) designed to support immune, gut, and skin health. While human stem cell exosomes remain an area of active exploration, our focus on non-human sources enables exceptional scalability and faster market access across diverse global regulatory landscapes.
More than a raw material provider, LUXTHERA is a premier Exosome CDMO partner. We offer tailored R&D, process development, GMP manufacturing, formulation, and our proprietary lyophilization services — preserving structural integrity and enhancing shelf stability, transportability, and clinical efficacy.
With a flexible, high-throughput manufacturing platform, LUXTHERAa empowers visionary companies to unlock the full therapeutic, aesthetic, and regenerative potential of exosomes — from concept to global commercialization.
Our experienced management team
Overcoming Traditional Extraction Challenges
Technology
Production
cGMP-Grade Exosome CDMO
The Importance of Growth Factors
LuxThera’s Growth Factor Breakthrough
Patented Antibody-Carrier System
We fuse growth factors with specialized antibodies to significantly extend their half-life and boost bioavailability
Human-Compatible Glycosylation
Produced in Chinese Hamster Ovary (CHO) cells for glycosylation patterns similar to human proteins, reducing immune responses and improving absorptio
Continuous Stimulation
Extended activity of growth factors promotes collagen, elastin, and hyaluronic acid production for long-term skin renewal
Overcome Common Lyophilization Limitations
LuxThera’s Patented Lyophilization
Optimized ultra-low temperature protocols and drying conditions maintain maximum bioactivity and structural stability
Proteins and other bioactive molecules remain intact, allowing quick reconstitution and sustained efficacy
to Various Needs
Choose from a bespoke range of lyophilization protectants or opt for solvent-free processing, ensuring optimal quality based on product requirements
.png)
.png)
Dr. Harvey Chin is a physician-scientist with clinical practice experience and a background in regenerative science research. Formerly a management consultant at McKinsey & Company, he advised clients across the pharma, biotech, and cell therapy CDMO sectors. He is also an inaugural Harvard Health Tech Innovation Fellow and the first physician in Taiwan to be recognized as a Forbes 30 Under 30 honoree.
.png)
Dr. Jean Cruz brings deep scientific and commercial expertise to the helm of our company. Formerly a project lead at McKinsey & Company and ZS, he specialized in R&D and commercial strategy across biotech and private equity. He earned his PhD in Applied Physics and Neuroscience from Cornell and held research and faculty roles at Harvard Medical School and MGH.
Dr. Chang Ho Yoon is a hospital internist, experienced researcher, and consultant for healthcare startups. Chang Ho obtained his Ph.D. in Biomedical Sciences and AI, and remains a researcher at both Oxford and Harvard Universities.
Dr. Thong Cao is a seasoned expert in drug product formulation and development, with a focus on drug product stability and scalability. Previously worked at Caribou Biosciences, Thong also led the Drug Product Team for Cell Therapy at Sanofi. He earned his Ph.D. in Biomedical Engineering from Cornell University
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.